GALT
Galectin Therapeutics Inc
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Galectin Therapeutics has 6 disclosed suppliers and 0 disclosed customers in SEC filings.
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
SentenceWe have contracted with Covance (now known as Fortrea) for assistance with the design and conduct of our NAVIGATE trial.
GALT 10-Kaccession 0001140361-26-012155
SentenceLate in 2021, we engaged three noted physicians – Dr. Chetan Bettegowda, from Johns Hopkins, and Dr. Nishant Agrawal and Dr. Ari Rosenberg, both from University of Chicago Medical Center – as consultants to help define the path forward in oncology.
GALT 10-Kaccession 0001140361-26-012155
SentenceLate in 2021, we engaged three noted physicians – Dr. Chetan Bettegowda, from Johns Hopkins, and Dr. Nishant Agrawal and Dr. Ari Rosenberg, both from University of Chicago Medical Center – as consultants to help define the path forward in oncology.
GALT 10-Kaccession 0001140361-26-012155
SentenceLate in 2021, we engaged three noted physicians – Dr. Chetan Bettegowda, from Johns Hopkins, and Dr. Nishant Agrawal and Dr. Ari Rosenberg, both from University of Chicago Medical Center – as consultants to help define the path forward in oncology.
GALT 10-Kaccession 0001140361-26-012155
SentenceThe trial did not meet its primary endpoint as measured using multi-parametric magnetic resonance imaging (LiverMultiScan (R) , Perspectum Diagnostics).
GALT 10-Kaccession 0001140361-26-012155
SentenceThese studies were conducted under the sponsorship of Providence Portland Medical Center's Earle A. Chiles Research Institute (EACRI).
GALT 10-Kaccession 0001140361-26-012155
—
—
Galectin Therapeutics Inc
3.31
Largest filed tie
—
Expected move
Inputsspot 3.32exp Nov 20ATM strike 2.5ATM straddle 1.70IV 288%